文献速递胃肠动力与功能性疾病

临床试验:研究α2δ配体PD-217,014在肠易激综合征患者中的疗效与安全性

Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha-2-Delta Ligand PD-217,014 in Patients With Irritable Bowel Syndrome.
PubMed 文献 · Aliment Pharmacol Ther · 2025-01-15

这项多中心、双盲、随机、安慰剂对照、平行组研究将330例罗马II标准定义的肠易激综合征患者随机分配至PD-217,014 150 mg每日两次、300 mg每日两次或安慰剂每日两次治疗4周。两种剂量均未改善腹痛/不适充分缓解的患者比例,次要终点结果相似,PD-217,014总体耐受良好。

要点

  • PD-217,014 150 mg或300 mg每日两次均未较安慰剂提高腹痛/不适充分缓解率。
  • 次要终点(腹痛、腹胀、排便频率/性状、总体评估)结果与主要终点相似。
  • 基线腹痛或焦虑水平与患者改善无关联,PD-217,014总体耐受良好。

核心结论

  • 这项首个大型剂量范围试验显示,PD-217,014对肠易激综合征患者及不同排便习惯亚型均无显著疗效, regardless of pain and anxiety levels(原文此处为英文,意为无论疼痛和焦虑水平如何)。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照、平行组研究。
  • 随机330例罗马II标准定义的肠易激综合征患者,年龄19-73岁,209例(65%)为女性。
  • 322例(98%)接受治疗,271例(84%)完成研究;321例符合罗马IV标准。
  • 随机分配至PD-217,014 150 mg每日两次、300 mg每日两次或安慰剂每日两次,治疗4周。
  • 主要疗效终点为应答者,定义为在至少50%的积极治疗期间腹痛/不适充分缓解。

主要发现

  • 在罗马II定义的总队列或罗马II和IV肠易激综合征排便习惯亚型中,PD-217,014两种剂量均未较安慰剂改善报告腹痛/不适充分缓解的参与者百分比。
  • 次要终点(腹痛、腹胀、排便频率/性状、肠易激综合征症状总体评估)结果相似。
  • 基线腹痛或焦虑水平与参与者改善无关联。
  • PD-217,014总体耐受良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite the emergence of drugs to treat irritable bowel syndrome (IBS), improving abdominal pain can still be challenging. α2δ ligands, such as gabapentin and pregabalin, are sometimes used off-label to tackle this problem. However, evidence for efficacy is limited, and no large-scale studies have been published. AIM: To study the efficacy of the α2δ ligand PD-217,014 in IBS. METHODS: This multi-centre, double-blind, randomised, placebo-controlled, parallel group study randomised participants with Rome II-defined IBS to 150 or 300 mg b.d. of PD-217,014 or placebo b.d. for 4 weeks. The primary efficacy endpoint was responder, defined as having adequate relief of abdominal pain/discomfort for ≥ 50% of the active treatment period. Key secondary endpoints were change from baseline in abdominal pain, bloating, stool frequency/consistency, and global assessment of IBS symptoms. RESULTS: We randomised 330 participants [aged 19-73 years; 209 (65%) female] satisfying Rome II criteria, 322 (98%) were treated, and of whom 271 (84%) completed the study. In this study, 321 satisfied Rome IV criteria. Neither dose of PD-217,014 improved the percentage of participants reporting adequate relief of abdominal pain/discomfort compared with placebo, either using the Rome II-defined total cohort or Rome II and IV IBS bowel habit sub-types. There were similar observations for secondary endpoints, and no association between abdominal pain or anxiety levels at baseline with participant improvement. PD-217,014 was generally well tolerated. CONCLUSION: This first large, dose-ranging trial examining the efficacy of PD-217,014 showed no significant efficacy in participants with IBS or bowel habit sub-types, irrespective of their pain and anxiety levels.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Houghton LA, Gao S, Gilbert SA, et al. Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha-2-Delta Ligand PD-217,014 in Patients With Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2025. PMID: 39812493. doi:10.1111/apt.18487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。